Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?-Reference-Cited by-同舟云学术

Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?

Published:2018-07-05 Issue:14 Volume:78 Page:1103-1110
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Rogasch Julian M.¹,Cash Hannes²,Zschaeck Sebastian³,Elezkurtaj Sefer⁴,Brenner Winfried¹⁵,Hamm Bernd⁶,Makowski Marcus⁶,Amthauer Holger¹,Furth Christian¹,Baur Alexander D. J.⁶^ORCID

Affiliation:

1. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Klinik für Nuklearmedizin; Berlin Germany

2. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Klinik für Urologie; Berlin Germany

3. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Klinik für Radioonkologie und Strahlentherapie; Berlin Germany

4. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institut für Pathologie; Berlin Germany

5. German Cancer Consortium; Deutsches Krebsforschungzentrum (DKFZ); Heidelberg Germany

6. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Klinik für Radiologie; Berlin Germany

Publisher

Wiley

Subject

Urology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pros.23685/fullpdf

Reference24 articles.

1. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer;Ghosh;J Cell Biochem,2004

2. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer;Afshar-Oromieh;Eur J Nucl Med Mol Imaging,2014

3. Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy;Eiber;J Nucl Med,2015

4. Treatment Outcomes from (68)Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET;Emmett;J Nucl Med,2017

5. (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment;Habl;Prostate,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value;Radiation Oncology;2024-07-29

2. A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer;Prostate Cancer and Prostatic Diseases;2024-05-31

3. Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET;Urologic Oncology: Seminars and Original Investigations;2024-04

4. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer;Urologic Oncology: Seminars and Original Investigations;2023-12

5. The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer;Journal of Nuclear Medicine;2023-06-29